Rhinoviral stimuli, epithelial factors and ATP signalling contribute to bronchial smooth muscle production of IL-33 by Jenny Calvén et al.
Calvén et al. J Transl Med  (2015) 13:281 
DOI 10.1186/s12967-015-0645-3
RESEARCH
Rhinoviral stimuli, epithelial factors 
and ATP signalling contribute to bronchial 
smooth muscle production of IL-33
Jenny Calvén1*, Hamid Akbarshahi1, Mandy Menzel1, Cemil Korcan Ayata2, Marco Idzko2, Leif Bjermer1 
and Lena Uller1
Abstract 
Background: Bronchial smooth muscle cells (BSMCs) from severe asthmatics have been shown to overexpress 
the Th2-driving and asthma-associated cytokine IL-33. However, little is known regarding factors involved in BSMC 
production of IL-33. Rhinovirus (RV) infections cause asthma exacerbations, which exhibit features of Th2-type inflam-
mation. Here, we investigated the effects of epithelial-derived media and viral stimuli on IL-33 expression in human 
BSMCs.
Methods: Primary human BSMCs from healthy (n = 3) and asthmatic (n = 3) subjects were stimulated with con-
ditioned media from primary human bronchial epithelial cells (BECs), double-stranded (ds)RNA, dsRNA/LyoVec, or 
infected with RV. BSMCs were also pretreated with the purinergic receptor antagonist suramin. IL-33 expression was 
analysed by RT-qPCR and western blot and ATP levels were determined in cell supernatants.
Results: RV infection and activation of TLR3 by dsRNA increased IL-33 mRNA and protein in healthy and asthmatic 
BSMCs. These effects were inhibited by dexamethasone. BSMC expression of IL-33 was also increased by stimulation 
of RIG-I-like receptors using dsRNA/LyoVec. Conditioned media from BECs induced BSMC expression of IL-33, which 
was further enhanced by dsRNA. BEC-derived medium and viral-stimulated BSMC supernatants exhibited elevated 
ATP levels. Blocking of purinergic signalling with suramin inhibited BSMC expression of IL-33 induced by dsRNA and 
BEC-derived medium.
Conclusions: RV infection of BSMCs and activation of TLR3 and RIG-I-like receptors cause expression and production 
of IL-33. Epithelial-released factor(s) increase BSMC expression of IL-33 and exhibit positive interaction with dsRNA. 
Increased BSMC IL-33 associates with ATP release and is antagonised by suramin. We suggest that epithelial-derived 
factors contribute to baseline BSMC IL-33 production, which is further augmented by RV infection of BSMCs and 
stimulation of their pathogen-recognising receptors.
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Background
Interleukin-33 (IL-33), a recently described member 
of the IL-1 cytokine family [1], has been forwarded as a 
potent driver of T-helper-2 (Th2)-type immunity and 
allergic inflammation [1–3]. Constitutive expression of 
IL-33 protein is predominantly found in nuclei of struc-
tural cell types, notably epithelial and endothelial cells 
[1, 4, 5]. Moreover, elevated levels of IL-33 have been 
demonstrated in  situ in bronchial epithelium as well as 
bronchial smooth muscle cells from subjects with severe 
asthma, implicating IL-33 in asthma pathogenesis [6, 7]. 
Further support of this role comes from murine models 
[3, 8, 9] and large-scale genome-wide association studies 
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in which asthma-susceptibility loci have been identi-
fied in the regions for IL33 and the cognate receptor for 
IL-33, IL1RL1 (i.e. ST2) [10, 11].
Release of IL-33 has principally been associated with 
cellular damage, proposing that IL-33 functions as an 
endogenous danger signal or alarmin [12]. However, a 
recent study demonstrated that exposure to the fun-
gus Alternaria Alternata resulted in IL-33 secretion 
from bronchial epithelial cells in the absence of cellular 
necrosis and that this secretion was mediated via auto-
crine release of ATP and purinergic P2-receptor (P2R) 
activation [13]. At high concentrations, extracellular 
ATP is also considered an alarmin and is proposed to 
be involved in allergen-driven lung inflammation [14, 
15]. Additionally, a pathophysiological role of ATP/P2R-
axis in chronic lung disease is supported by findings of 
accumulated levels of ATP both in the airways of patients 
with asthma and chronic obstructive pulmonary disease 
(COPD) as well as in animal models of airway inflamma-
tion [14–18].
Rhinovirus (RV) infections are main triggers of asthma 
exacerbations [19, 20]. Double-stranded RNA (dsRNA) 
intermediates formed during RV replication initiate host 
innate immune responses via activation of pattern rec-
ognition receptors (PRRs), including toll-like receptor 
3 (TLR3) and the retinoic acid-inducible gene-I (RIG-
I)-like receptors RIG-I and melanoma-differentiation 
associated-gene 5 (MDA5) [21]. Previous studies have 
reported TLR3-induced IL-33 expression [22–24], but 
data regarding RV-induced IL-33 production and spe-
cific involvement of dsRNA-sensing receptors are cur-
rently limited [25]. Further, to our knowledge it has not 
been described if P2R signalling may have a role in TLR3-
mediated IL-33 induction.
In the last decades, accumulated evidence supports an 
active role for bronchial smooth muscle cells (BSMCs) in 
immunomodulation and airway inflammation. Findings 
include expression of PRRs and secretion of a wide rep-
ertoire of cytokines and other mediators in response to 
external stimuli [26, 27]. We recently demonstrated that 
BSMCs express functional RIG-I-like receptors in addi-
tion to the previously described TLR3, and that activa-
tion of these receptors by viral stimuli results in BSMC 
production of type I and III interferons [28]. In the pre-
sent study we hypothesized that BSMC expression of 
IL-33 may be induced by epithelial-derived factors as well 
as by viral stimuli. Hence, we have examined effects of 
bronchial epithelial conditioned media and of viral stim-
uli, including RV infection and specific ligands for TLR3 
and RIG-I-like receptors on primary human BSMCs from 
healthy and asthmatic individuals.
Methods
Primary cell cultures
Primary human BSMCs from three healthy subjects and 
three subjects with mild to moderate asthma were com-
mercially obtained from Lonza (Walkersville, MD, USA) 
as cryopreserved cells. BSMCs were cultured under 
standard conditions (5  % CO2 and 37  °C) in smooth 
muscle growth medium supplemented with Single-
Quots and 5 % FBS (SmGM-2; Clonetics, San Diego, CA, 
USA) and used in experiments at passage 4–8. Primary 
human bronchial epithelial cell (BEC) cultures from four 
individuals with asthma were established from epithe-
lial brushings obtained by bronchoscopy as previously 
described [29]. BECs were cultured under standard con-
ditions in bronchial epithelial growth medium supple-
mented with SingleQuots (BEGM; Clonetics, San Diego, 
CA, USA) and used at passage 2–3 for the generation of 
BEC-derived conditioned medium. Ethical approval was 
obtained from the regional ethical review board at Lund 
University Sweden, and all study participants provided 
written informed consent.
Generation of BEC‑derived conditioned media
BECs were seeded into collagen coated 12-well plates 
(Nunc, Life Technologies, Carlsbad, CA, USA) and 
grown to confluency. The growth medium was then 
replaced with 1  ml/well of bronchial epithelial basal 
medium (BEBM; Clonetics) supplemented with 1  % 
insulin-transferrin-selenium and 0.1 % BSA. Some BECs 
were additionally treated with 10 μg/ml of the synthetic 
dsRNA analogue polyinosine-polycytidylic acid (Poly 
(I:C); InvivoGen San Diego, CA, USA). After 24 h incu-
bation, control and dsRNA-generated conditioned media 
were subsequently collected, centrifuged to remove cell 
debris and stored in −80 °C until further use.
Stimulation and RV infection of BSMCs
BSMCs were seeded into 12-well plates and when 
80–90  % confluent, the growth medium was replaced 
with SmGM-2 containing reduced serum (0.5 % FBS) for 
24  h before the cells were stimulated with BEC-derived 
conditioned media (diluted 1:100 to 1:10 in serum-
reduced SmGM-2) alone or in combination with 10 μg/
ml dsRNA [Poly (I:C)]. BEBM diluted 1:10 in serum-
reduced SmGM-2 was used as vehicle control. Similarly, 
BSMCs were stimulated with a range of concentrations of 
dsRNA, dsRNA/LyoVec (Poly (I:C) in complex with the 
transfection agent LyoVec; InvivoGen), non-hydrolys-
able ATP (ATP-γ-S; Sigma-Aldrich, Gillingham, UK) or 
medium control (serum-reduced SmGM-2). Addition-
ally, BSMCs were infected with human RV1B at different 
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levels of multiplicity of infection (MOI) as previously 
described [28], treated with medium control or ultravio-
let (UV)-inactivated RV (UVi-RV; non-infectious virus 
control) corresponding to the highest MOI used for RV 
infection. When indicated, 10 μg/ml chloroquine, 1 μg/
ml dexamethasone or 10–100  μM suramin (all from 
Sigma-Aldrich) was added 1  h prior to stimulation or 
RV infection and was present until the end of the experi-
ment. At the indicated time points, cell supernatants 
were collected for ATP and protein quantification and 
cells lysed and harvested for mRNA or protein expres-
sion analyses.
IL‑33 mRNA analysis by real‑time qPCR
Total RNA was extracted from primary BSMCs, reverse 
transcribed and analysed with real-time qPCR as previ-
ously described [28]. The primer sequences used to detect 
IL-33 were supplied by Primerdesign (Southampton, UK) 
and were as follows: AAAGAAAGATAAGGTGTTACT 
GAGTTA (forward) and GCAACCAGAAGTCTTTTG 
TAGG (reverse). IL-33 was normalised to the geometric 
mean of two reference genes, ubiquitin c (UBC) and glyc-
eraldehyde 3-phosphate dehydrogenase (GAPDH), and 
relative gene expression compared to control was ana-
lysed using the ΔΔCt method.
Western blot analysis of IL‑33 protein
Total protein was extracted from cell lysates using a sam-
ple buffer for western blot containing 1  % TritonX-100, 
10  mM Tris–HCl, 50  mM NaCl, 5  mM EDTA, 30  mM 
sodium pyrophosphate, 50  mM NaF, 0.1  mM Na3VO4, 
and complete protease inhibitor cocktail (Sigma-Aldrich). 
Protein concentration was measured using BCA protein 
assay reagent kit (PIERCE ThermoScientific). Lysates 
were dissolved in Laemmli buffer, boiled and electro-
phoretically separated in a 12  % SDS-PAGE gel before 
transferred to an Immobilon-P Membrane, PVDF (Merck 
Millipore). Blots were blocked in 5 % (w/v) milk in Tris-
buffered saline Tween-20 and incubated overnight at 4 °C 
with the primary antibody, anti-IL-33 antibody Nessy-1 
clone (N1) (Enzo Life Sciences). Following washing, the 
membranes were incubated for 1  h with the secondary 
HRP–linked horse-anti-mouse antibody (Cell Signaling 
Technology). Immunoblotted proteins were visualised by 
SuperSignal West Dura Substrate (PIERCE ThermoSci-
entific) using LI-COR Odyssey Fc Imager (LI-COR Bio-
sciences) and Image studio Vr 2.0 software.
ATP and IL‑33 release
ATP and IL-33 were measured in cell supernatants using 
an ATP assay from BioThema (Sweden) or a DuoSet 
ELISA from R&D Systems (Abingdon, UK) according to 
the manufacturer’s descriptions, respectively.
Statistical analysis
Data were analysed using the software GraphPad Prism 
version 6.0 (San Diego, CA, USA) and expressed as 
mean value with SEM. Significant variations between 
paired groups were determined by the non-parametric 
tests Friedman´s one-way ANOVA and the Wilcoxon 
matched-pairs signed ranks test, while the Mann–
Whitney test was used to analyse differences between 
unpaired groups. P values of less than 0.05 were consid-
ered statistically significant.
Results
Conditioned media from bronchial epithelial cells trigger 
expression of IL‑33 in BSMCs and concurrent stimulation 
with dsRNA enhances the response
To address our hypothesis that epithelial mediators may 
induce expression of IL-33 in BSMCs, we stimulated 
BSMCs with conditioned media obtained from non-
treated or dsRNA-treated bronchial epithelial cells. Con-
centration-dependent effects on IL-33 mRNA expression 
were induced in healthy BSMCs at 3 h (Fig. 1a) and fur-
ther augmented at 24  h (Fig.  1b). Healthy BSMCs were 
also stimulated directly with dsRNA, either alone or in 
combination with epithelial conditioned media in an 
optimal concentration of 1:10. dsRNA alone induced 
modest expression of IL-33 mRNA at 3 h (Fig. 1c), which 
was more pronounced at 24  h (Fig.  1d). At 24  h, direct 
stimulation of BSMCs with dsRNA in combination with 
conditioned media from either non-treated or dsRNA-
treated epithelial cells caused an additive induction of 
IL-33 expression (Fig. 1d). Since BSMCs are known to be 
in juxtaposition with the bronchial epithelium in asthma, 
we investigated the effect of epithelial conditioned 
media also on BSMCs from asthmatic subjects. Similar 
to in healthy BSMCs, IL-33 expression was induced by 
dsRNA and/or conditioned media at 3  h (Fig.  1e) and 
further increased at 24 h (Fig. 1f ). Although no statisti-
cal significance could be achieved, the observed IL-33 
responses at 24  h tended to be more pronounced in 
BSMCs from asthmatic subjects (Fig. 1f ) compared with 
healthy BSMCs (Fig.  1d). Interestingly however, in con-
trast to the observed effect in healthy BSMCs (Fig. 1a–d), 
IL-33 expression in asthmatic BSMCs at 24 h was more 
increased after stimulation with conditioned medium 
from dsRNA-treated epithelial cells compared to condi-
tioned medium from non-treated epithelial cells (Fig. 1f ).
IL‑33 is produced by BSMCs in response to specific ligands 
for TLR3 and RIG‑I‑like receptors
We have previously shown that BSMCs similar to 
bronchial epithelial cells express TLR3 and RIG-I-like 
receptors and that stimulation of these PRRs leads to 
significant BSMC production of antiviral interferons 









































































































































































































































































































































































Fig. 1 Bronchial smooth muscle cell (BSMC) expression of IL-33 is induced by epithelial conditioned media and further enhanced by dsRNA. To 
establish an optimal concentration of epithelial conditioned media, BSMCs from healthy subjects were stimulated with different dilutions of con-
ditioned media from either non-treated (cond med) or dsRNA-treated (dsRNA-cond med) bronchial epithelial cells and mRNA expression of IL-33 
was analysed by RT-qPCR after 3 and 24 h (a, b). IL-33 expression after stimulation with 10 μg/ml dsRNA alone or in combination with epithelial 
conditioned media was analysed in both healthy (c, d) and asthmatic (e, f) BSMCs. Epithelial basal medium diluted 1:10 in BSMC medium was used 
as vehicle control. Data are presented as mean with SEM and n = 3–6 independent experiments from three BSMC donors. *p ≤ 0.05, **p ≤ 0.01 and 
***p ≤ 0.001 compared to vehicle if not otherwise indicated
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[28]. As demonstrated above (Fig.  1b–d), dsRNA also 
induced IL-33 expression in both healthy and asthmatic 
BSMCs. To further investigate a potential role of TLR3 
and RIG-I-like receptors in BSMC production of IL-33, 
healthy BSMCs were stimulated with different doses of 
dsRNA and dsRNA/LyoVec, primarily activating TLR3 
and RIG-I-like receptors respectively. At 3  h a modest 
IL-33 expression was only induced by 10 μg/ml dsRNA 
(Fig.  2a), but at 24  h both dsRNA and dsRNA/LyoVec 
concentration-dependently increased expression of IL-33 
mRNA as well as IL-33 protein (Fig.  2b, d). The TLR3 
inhibitor chloroquine reduced dsRNA-induced IL-33 
expression (Fig.  2b, d). Further, we found that dexa-
methasone inhibited dsRNA-induced IL-33 expression 
in BSMCs from both healthy (Fig.  2c, d) and asthmatic 
subjects (Fig. 2c).
RV infection triggers production of IL‑33 by BSMCs
Next, we infected BSMCs with RV. RV infection induced 
a dose-dependent increase of IL-33 mRNA in BSMCs 
from healthy individuals at 24  h (Fig.  3a) being further 
enhanced 48  h post infection (Fig.  3b). Increased IL-33 
protein also occurred (Fig.  3c). Further, IL-33 was also 
significantly induced in RV-infected BSMCs from asth-
matic donors at 24  h (Fig.  3d, e). Release of low levels 
of IL-33 protein was detected from RV-infected BSMCs 
only and occurred in parallel with RV-induced cytopathic 
effects (unpublished observations). Infection with UV-
irradiated RV did not elicit an IL-33 response (Fig.  3a, 
c–e), suggesting that RV-induced IL-33 is replication 
dependent. Chloroquine tended to reduce RV-induced 
IL-33 expression proposing involvement of TLR3 sig-
nalling (Fig. 3f ). Similar to dsRNA-induced IL-33, dexa-
methasone inhibited RV-induced IL-33 expression in 
BSMCs from both healthy and asthmatic individuals 
(Fig. 3f ).
IL‑33 induced by viral stimulation and epithelial condition 
medium in BSMCs is blocked by suramin, a broad inhibitor 
of purinergic signalling
When analysing BSMC supernatants we found that 
dsRNA induces immediate release of ATP above baseline 
levels, peaking 5 min or earlier after stimulation (Fig. 4a). 
























































































































































































































































Fig. 2 Specific ligands for TLR3 and RIG-I-like receptors trigger production of IL-33 in BSMCs. BSMCs from healthy subjects were stimulated with 
different concentrations of dsRNA and dsRNA/LyoVec (dsRNA/LV). IL-33 mRNA expression (a, b) was analysed after 3 and 24 h by RT-qPCR and IL-33 
protein was determined by western blot after 24 h (d). Cells were also pretreated with 10 μg/ml of the TLR3 inhibitor chloroquine (Cq) (a, b and d). 
The effect of 1 μg/ml dexamethasone (Dex) on 10 μg/ml dsRNA-induced IL-33 expression was evaluated in healthy (c, d) and asthmatic BSMCs (c) 
after 24 h stimulation. Data are presented as mean with SEM and n = 6 independent experiments from three BSMC donors. *p ≤ 0.05, **p ≤ 0.01 
and ***p ≤ 0.001 compared to control if not otherwise indicated and ###p compared to 10 μg/ml dsRNA. A representative western blot image of 
IL-33 protein is shown
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from RV-infected BSMCs compared to control cells 
(Fig. 4b). To test if ATP could induce IL-33 expression in 
BSMCs, we stimulated the cells with non-hydrolysable 
ATP (ATP-γ-S) and found increased IL-33 mRNA after 
24  h (Fig.  4c). To further show that ATP is involved in 
dsRNA-induced IL-33 production we treated BSMCs 
with suramin, a broad inhibitor of purinergic signal-
ling. We found concentration-dependent inhibition by 
suramin of the dsRNA-induced IL-33 expression at both 
mRNA (Fig. 4d) and protein levels (Fig. 4e). We then ana-
lysed the ATP content in bronchial epithelial conditioned 
medium and found a significantly higher concentration 
of ATP compared to non-conditioned medium (Fig. 4f ). 
Further, when suramin was added to BSMCs prior to 
bronchial epithelial conditioned medium, IL-33 expres-
sion in BSMCs was significantly reduced (Fig. 4g).
Discussion
Recent evidence highlights that BSMCs are not only 
responsible for regulating bronchomotor tone, but have 
many regulatory functions related to inflammation and 
innate immunity in the airways [26, 27]. In the present 
study we report for the first time that IL-33 production 
is increased in healthy and asthmatic BSMCs upon acti-
vation of TLR3 and RIG-I-like receptors as well as after 
RV infection and that this response is sensitive to corti-
costeroid treatment. We also show that BSMC expression 
of IL-33 is induced by factor(s) released by bronchial epi-
thelial cells and further augmented by rhinoviral stimuli. 
Moreover, our results suggest that the cellular metabo-
lite ATP is involved in mediating IL-33 expression since 
this mediator is produced upon RV infection and TLR3 
activation, elevated in epithelial conditioned medium 
and pharmacological modulation involving blocking of 
purinergic receptors reduces the present IL-33 induction 
in BSMCs.
To our knowledge only one study, recently published 
by Jackson and colleagues, has reported RV infection-
induced IL-33 production by human airway cells, and 
that study involved primary bronchial epithelial cells [25]. 
Although the bronchial epithelium is the main target for 












































































































































































































































Fig. 3 IL-33 is produced by BSMCs upon infection with RV. BSMCs from healthy (a–c) and asthmatic subjects (d, e) were infected with RV at differ-
ent doses (MOI multiplicity of infection). Expression of IL-33 mRNA and protein were analysed by RT-qPCR 24 and 48 h post infection and by western 
blot 24 h post infection. UVi-RV = UV inactivated RV corresponding to the highest dose of RV used. The effects of chloroquine (10 μg/ml) and 
dexamethasone (1 μg/ml) on RV-induced (0.5 MOI) IL-33 expression were evaluated in healthy and asthmatic BSMCs 24 h post infection (f). Data are 
presented as mean with SEM and n = 3–6 independent experiments from three BSMC donors. *p ≤ 0.05 and **p ≤ 0.01 compared to control if not 
otherwise indicated. Representative western blot images of IL-33 protein are shown
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in  situ in diseased lower airways possibly reflecting a 
compromised epithelial barrier occurring in asthma 
and COPD [30, 31]. Here we demonstrate that IL-33 is 
produced upon RV infection of primary human BSMCs 
from healthy and asthmatic subjects. Since UV-irradiated 
RV did not induce IL-33 this effect is likely to be repli-
cation dependent. In agreement with involvement of the 
biologically active intermediate dsRNA, chloroquine, 
an agent that inhibits endosomal TLR3 activation [32], 
partly reduced the present IL-33 response to RV. Further, 
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ATP release after dsRNA stimulation 
Fig. 4 Blocking purinergic signalling inhibits BSMC expression of IL-33 induced by dsRNA and epithelial condition medium. BSMCs were stimulated 
with 10 μg/ml dsRNA for 5–60 min and ATP was analysed in cell supernatants and data related to that of control samples (a). ATP release was also 
measured in BSMC supernatants 24 h after RV-infection (b). BSMC expression of IL-33 mRNA was analysed by RT-qPCR 24 h after stimulation with 
non-hydrolysable ATP (ATP-γ-S) (c). The effect of the purinergic inhibitor suramin (Sur) on dsRNA-induced IL-33 expression was evaluated at both 
mRNA (d) and protein (e) levels with RT-qPCR and western blot respectively. ATP was measured in bronchial epithelial conditioned medium (n = 4 
donors) and compared to non-conditioned medium (control) (f) and the effect of suramin on conditioned medium-induced IL-33 mRNA (g) was 
analysed 24 h after stimulation. Data are presented as mean with SEM and n = 2–6 independent experiments from two or three BSMC donors. 
*p ≤ 0.05, **p ≤ 0.01, and ***p ≤ 0.001 compared to control if not otherwise indicated and ###p ≤ 0.001 compared to 10 μg/ml dsRNA. A repre-
sentative western blot image of IL-33 is shown
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by employment of agonists primarily activating either 
TLR3 (dsRNA) or RIG-I-like receptors (dsRNA/LyoVec), 
we demonstrated that both these RV infection-mimick-
ing PRR ligands induced IL-33 expression in BSMCs. 
The discrepancies between the mRNA and protein data 
comparing the two ligands at 24 h may be explained by 
different receptor-ligand kinetics as observed in our pre-
vious study where stronger responses with dsRNA/Lyo-
Vec occurred later than with dsRNA and corresponded 
with upregulated expression of RIG-I and MDA5 [28]. 
Our data on RIG-I-like receptor-induced IL-33 is in 
accord with a previous study by Polumuri and colleagues 
who observed particularly robust transcription of IL-33 
in murine macrophages upon stimulation with RIG-I-
like receptor agonists [22]. Since the effect of the TLR3 
inhibitor chloroquine on RV-induced IL-33 was only 
partial, our data further implies a role also for cytosolic 
RIG-I-like receptors in RV-induced IL-33 production in 
BSMCs. However, future studies are needed to address 
this question more in detail.
Préfontaine and colleagues have previously described 
airway smooth muscle cell overexpression of IL-33 in 
endobronchial biopsy specimens from severe asth-
matics [7]. In asthma, especially in the severe state, the 
airway smooth muscle also exhibits extensive remod-
elling including proliferation and migration leading to 
increased smooth muscle mass [33, 34]. Such alterations 
may position BSMCs in closer proximity to the airway 
epithelial lining potentially enhancing epithelial-smooth 
muscle crosstalk. This possibility supports a potential 
role of the present finding that factors spontaneously 
released by bronchial epithelial cells increased IL-33 
expression in BSMCs. Hence, epithelium-derived fac-
tors may in part be responsible for baseline expression 
of IL-33 in juxtapositioned bronchial smooth muscle. 
Interestingly, asthmatic BSMCs exhibited even more 
pronounced IL-33 expression after stimulation with con-
ditioned medium derived from epithelial cells treated 
with dsRNA. Although the molecular mechanism under-
lying this finding is currently unclear, the observation 
that activation of PRRs in BECs enhance IL-33 produc-
tion in BSMCs from asthmatic but not healthy subjects 
is intriguing and merits further investigation in future 
studies. Moreover, concurrent additional stimulation of 
BSMCs with dsRNA further increased all responses to 
epithelial conditioned media, proposing that epithelial-
induced IL-33 expression in BSMCs may be potentiated 
by exogenous microbial or endogenous injury-associated 
TLR3 ligands, such as dsRNA. The somewhat surpris-
ing discovery that epithelial cells already at baseline pro-
duce factors that increase BSMC IL-33 expression needs 
follow-up by future studies. A range of epithelial chal-
lenges can be listed, including the present viral stimuli, as 
candidates that potentially could increase the influence 
of epithelial cells on BSMC expression and production of 
IL-33.
In the present study we observed that asthmatic 
BSMCs in comparison to healthy cells tended to have an 
elevated IL-33 response after stimulation with epithelial 
conditioned media and dsRNA, and possibly after RV 
infection too. However, a larger number of study subjects 
would be required to investigate if statistically significant 
disease-related differences exist. Further, our observa-
tion that viral-induced IL-33 expression in BSMCs from 
healthy as well as asthmatic subjects was sensitive to dex-
amethasone treatment contrasts to the study by Préfon-
taine and colleagues where the same corticosteroid failed 
to reduce the transcription of IL-33 in TNF-α-stimulated 
airway smooth muscle cells [7]. These discrepancies may 
in part relate to the nature of the stimuli or the smooth 
muscle cell population studied. Chang and colleagues 
recently reported that airway smooth muscle cells from 
severe asthmatics have impaired nuclear translocation 
of the glucocorticoid receptor, which may provide one 
explanation to the corticosteroid insensitivity found in 
these patients [35]. Whether or not the effect of corticos-
teroids on viral-induced IL-33 is compromised in BSMCs 
from severe asthmatics is something to consider for 
future studies.
Extracellular ATP in the airways has been implicated 
in both asthma and COPD pathogenesis [14–17]. Studies 
also show that release of ATP into the extracellular space 
upon exposure to allergen, smoke or viral infections may 
promote an inflammatory microenvironment [14, 15, 
17, 18, 36]. In the present study extracellular ATP levels 
were increased rapidly after stimulation of BSMCs with 
dsRNA and elevated in supernatants from RV-infected 
BSMCs. By pretreating BSMCs with suramin, a broad-
spectrum purinergic receptor antagonist, we could fur-
ther demonstrate that IL-33 expression in response to 
dsRNA was abrogated in a concentration-dependent 
manner, implying a role for ATP signalling. Recently, 
Kouzaki and colleagues reported that exposure of pri-
mary human bronchial epithelial cells to the fungal aller-
gen Alternaria Alternata leads to noncytotoxic release 
of pre-formed IL-33 and proposed that this response 
involved ATP release and subsequent stimulation of 
purinergic P2 receptors [13]. However, to our knowledge, 
our observation on involvement of ATP in TLR3-medi-
ated enhanced IL-33 production is novel.
Based on our observations including the finding that 
exogenous ATP could trigger BSMC expression of IL-33, 
we speculated that ATP released from bronchial epithe-
lial cells also could be involved in the enhanced IL-33 
expression found in BSMCs. In support of this hypoth-
esis, we could detect significantly higher levels of ATP in 
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conditioned medium from bronchial epithelial cells com-
pared to non-conditioned epithelial medium. Further, 
pretreatment of BSMCs with the broad P2R-antagonist 
suramin reduced IL-33 expression in response to both 
epithelial conditioned medium alone and to the combi-
nation of conditioned medium and dsRNA. Thus, our 
findings suggest the involvement of ATP, likely in concert 
with other epithelial-derived mediators, in the enhanced 
IL-33 expression observed in BSMCs challenged with 
bronchial epithelial conditioned media.
Conclusions
In summary, in this study we demonstrate BSMC pro-
duction of the immunoregulatory cytokine IL-33, which 
has been forwarded as a potential disease factor in 
asthma. Further, we show that conditioned media from 
bronchial epithelial cells as well as RV infection and stim-
ulation with viral infection mimics acting on TLR3 and 
RIG-I-like receptors increase IL-33 in BSMCs from both 
healthy and asthmatic individuals. The present data sug-
gest that epithelial mediators may induce baseline BSMC 
IL-33 gene expression and that augmented expression 
and production of IL-33 are caused by RV infection of 
BSMCs and stimulation of TLR3 and RIG-I-like recep-
tors. We further suggest that ATP is involved as an epi-
thelial-derived mediator of BSMC IL-33 expression and, 
similarly, the ATP/P2R-axis may be involved in the pre-
sent viral stimuli-induced effects directly on BSMCs.
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